Articles tagged with Circulating Tumor Cells
French researchers have reported the strongest proof yet that circulating tumor cells found in patient blood are linked to poor outcomes. The study suggests using a threshold of 1 CTC for defining high-risk patients, supporting its use in non-metastatic breast cancer patients.
Massachusetts General Hospital has entered into a collaborative agreement with Veridex LLC to develop novel technologies for capturing and characterizing circulating tumor cells. The goal is to create non-invasive methods for cancer detection and early diagnosis.
A study published by the American Association for Cancer Research found that circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients are associated with an increased risk of relapse and death. The presence of CTCs is predicted to be a significant predictor for disease-free and overall survival.
A new disposable device based on microfluidics can efficiently capture cancer cells overexpressing HER2, enabling therapy with trastuzumab. The device offers a non-invasive alternative to current methodologies and has shown promising results in early studies.
A novel approach detects genetically abnormal cells in the blood of non-small cell lung cancer patients, increasing with disease severity. The study suggests that these circulating cells could be used to diagnose lung cancer earlier and monitor response to therapy.
Researchers found that pancreatic cancer patients with circulating tumor cells tend to have worse outcomes, and some types of cells may predict poorer survival. The presence of MUC1 protein-expressing circulating tumor cells is particularly associated with shorter overall survival.
A new study found that the number of circulating tumor cells in a patient's blood directly correlates with their survival time in metastatic breast cancer. The research suggests that monitoring these cells could improve personalized therapy for patients.
Researchers emphasize the need for improved technologies to detect circulating tumor cells (CTC's) due to their metastasizing ability. The current standardized test, CellSearch, has limitations and can only count CTC's, making it essential to explore additional technologies.
Researchers developed a simple biological imaging system to visualize live tumor cells in peripheral blood. The technology reflects the tumor burden, decreasing upon primary tumor removal, holding promise for clinical benefit.
Researchers at UCLA developed a novel camera that captures images at 6 million frames per second, overcoming conventional camera limitations. The camera's optical image amplification enables continuous real-time imaging of rapid phenomena in physics, chemistry, and biology.
Researchers found that circulating tumor cell counts accurately predict treatment response and survival in castration-resistant prostate cancer. Patients with declining cell counts showed improved prognosis, reflecting potential therapy benefits.
A trial found that circulating tumor cells in the blood of patients with metastatic prostate cancer can predict how well they will respond to chemotherapy. Patients with more than five tumor cells per blood sample had a worse prognosis, while those whose CTC number went down fared better.
A large multicenter study examined circulating tumor cells in patients with metastatic colorectal cancer, showing their predictive value for survival and cancer progression. Patients with fewer than 3 CTCs had superior median survival times compared to those with detectable CTCs.
A study using CellSearch technology found that women with high tumor cell levels in their blood had poor treatment outcomes. Women whose circulating tumor cell levels dropped after starting therapy fared much better.
A new study has found that patients with high levels of circulating tumor cells in their blood have shorter progression-free survival and overall survival rates compared to those with low levels. The presence of these cells can predict prognosis more accurately than other factors, allowing for more tailored treatment decisions.
Women with circulating tumor cells in their blood have a median survival of less than 24 months, compared to over 24 months without them. The presence of cancer cells in the blood predicts prognosis more accurately than other factors, indicating a possible link between blood-circulating tumor cells and aggressive breast cancer.